Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets (“[…***…]” in...Distribution and Commercialization Agreement • August 17th, 2020 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This Distribution and Commercialization Agreement (the “Agreement”) is made effective as of the Effective Date (as defined herein) by and between Adamis Pharmaceuticals Corporation, a corporation organized under the laws of Delaware, with an office located at 11682 El Camino Real, Suite #300, San Diego, California 92130 (“Company”) and USWM, LLC, a limited liability company organized under the laws of Delaware, with an office at [***] (“USWM”). Company and USWM may hereafter be referred to collectively as the “Parties” and individually as a “Party”.
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets (“[…***…]” in...Termination and Transfer Agreement • August 17th, 2020 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Termination and Transfer Agreement (this “Agreement”) is made and entered into as of May 11, 2020 (the “Effective Date”) by and between Adamis Pharmaceuticals Corporation (“Adamis”), a corporation organized under the laws of Delaware (the “Company”), with an office located at 11682 El Camino Real, Suite #300, San Diego, CA 92130 and Sandoz Inc. (“Sandoz”) with an address at 100 College Road, West Princeton, NJ 08540. Sandoz and Adamis may each be referred to herein as a “Party” or, collectively, as the “Parties.”
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets (“[…***…]” in...Transition Services Agreement • August 17th, 2020 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This Transition Services Agreement (the “Agreement”) is entered into as of June 1, 2020 (the “Effective Date”), by and between Adamis Pharmaceuticals Corporation, a Delaware corporation, with an office located at 11682 El Camino Real, Suite #300, San Diego, CA 92130 (“Adamis”), USWM, LLC, a Delaware limited liability company, with an office at [***] (“USWM”) and Sandoz Inc., a Colorado corporation, with offices at 100 College Road West, Princeton, New Jersey 08540 (“Sandoz”). Adamis, USWM and Sandoz are each referred to individually as a “Party” and together as the “Parties”.
LICENSE AGREEMENTLicense Agreement • August 17th, 2020 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • California
This License Agreement (“Agreement”) is entered into by and between Matrix Biomed, Inc. (“Licensor”), a Delaware corporation having a place of business at 2301 Dupont Drive, Suite 420, Irvine, California 92612, and Adamis Pharmaceuticals (“Licensee”), a Delaware corporation having a principal place of business at 11682 El Camino Real, Suite 300, San Diego, California 92130. Licensor and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties”.
